Dec 16 2009
Nanotherapeutics, Inc., a privately held biopharmaceutical company,
announced that it has acquired in bankruptcy proceedings two late stage
clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation
and PRX-3140 from EPIX Pharmaceuticals, Inc. Ramoplanin - an oral
antibiotic for the treatment of Clostridium difficile-associated
disease (CDAD) - is entering Phase 3 trials. PRX-3140 - an
orally-bioavailable Alzheimer’s treatment - is in Phase 2 clinical
studies. Nanotherapeutics also acquired the U.S. and foreign patent
estates covering each clinical program.
Source Nanotherapeutics